“…This enabled multiple large trials to be conducted in parallel [ 1 ] and trial timelines to be compressed by running the usually distinct phases I to III of clinical trials, as well as licensure processes, partly in tandem [ 3 ]. Meanwhile, manufacturing of multiple candidates began at scale so that large stockpiles of vaccines were available immediately upon licensure to begin Phase IV and national vaccination programmes immediately [ 3 ]. In sum, the fast success was a combination of sustained long-term investment in research infrastructure, large sums of newly available funding, government intervention, and some good fortune that, as a coronavirus, the pandemic came from a family of viruses that was being studied [ 1 , 2 ].…”